Published in PLoS One on August 07, 2013
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis (2014) 1.56
Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. Cell Host Microbe (2016) 1.25
Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study. AIDS (2014) 0.94
Residual inflammation and viral reservoirs: alliance against an HIV cure. Curr Opin HIV AIDS (2016) 0.90
A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. PLoS Pathog (2016) 0.90
Prolonged Antiretroviral Therapy Preserves HIV-1-Specific CD8 T Cells with Stem Cell-Like Properties. J Virol (2015) 0.88
A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy. J Virol (2015) 0.87
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells. PLoS Pathog (2015) 0.86
HIV-specific CD8+ T cells and HIV eradication. J Clin Invest (2016) 0.85
CD8+ T cells from HLA-B*57 elite suppressors effectively suppress replication of HIV-1 escape mutants. Retrovirology (2013) 0.84
HIV-1 latency and virus production from unintegrated genomes following direct infection of resting CD4 T cells. Retrovirology (2016) 0.81
Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS (2015) 0.81
Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open Forum Infect Dis (2016) 0.80
Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. Expert Rev Anti Infect Ther (2014) 0.79
Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification. J Immunol (2015) 0.79
Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy. PLoS One (2016) 0.78
Elimination of Latently HIV-infected Cells from Antiretroviral Therapy-suppressed Subjects by Engineered Immune-mobilizing T-cell Receptors. Mol Ther (2016) 0.78
Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. J Int AIDS Soc (2017) 0.76
Pharmacologic HIV-1 Nef blockade promotes CD8 T cell-mediated elimination of latently HIV-1-infected cells in vitro. JCI Insight (2017) 0.75
Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science (1997) 15.12
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A (2000) 11.51
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol (2002) 10.37
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol (2000) 8.62
Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 6.29
In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med (1995) 6.26
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A (1998) 5.48
HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A (2007) 4.96
Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol (2006) 4.27
Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA (2010) 3.14
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Perforin expression directly ex vivo by HIV-specific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog (2010) 2.99
Molecular characterization, reactivation, and depletion of latent HIV. Immunity (2003) 2.80
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J Virol (1993) 2.22
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation. J Virol (2011) 2.18
Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J Immunol (2009) 2.17
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog (2006) 2.08
Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS (2000) 2.04
Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods (2009) 1.91
Elite suppressors harbor low levels of integrated HIV DNA and high levels of 2-LTR circular HIV DNA compared to HIV+ patients on and off HAART. PLoS Pathog (2011) 1.77
Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J Virol (2004) 1.64
Qualitative features of the HIV-specific CD8+ T-cell response associated with immunologic control. Curr Opin HIV AIDS (2011) 1.63
Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. J Virol (2010) 1.60
Elite control of HIV infection: implications for vaccine design. Expert Opin Biol Ther (2009) 1.59
Infrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers. Clin Infect Dis (2010) 1.50
Productive human immunodeficiency virus type 1 infection in peripheral blood predominantly takes place in CD4/CD8 double-negative T lymphocytes. J Virol (2007) 1.36
Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog (2012) 1.34
Mechanisms of HIV latency: an emerging picture of complexity. Curr HIV/AIDS Rep (2010) 1.33
Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials. AIDS (2012) 1.27
Plasma human immunodeficiency virus RNA below 40 Copies/mL is rare in untreated persons even in the first years of infection. J Infect Dis (1999) 1.23
Effect of therapeutic HIV recombinant poxvirus vaccines on the size of the resting CD4+ T-cell latent HIV reservoir. AIDS (2011) 1.20
The CXCR4-tropic human immunodeficiency virus envelope promotes more-efficient gene delivery to resting CD4+ T cells than the vesicular stomatitis virus glycoprotein G envelope. J Virol (2009) 1.20
Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome. PLoS One (2009) 1.16
Inhibition of HIV-1 integration in ex vivo-infected CD4 T cells from elite controllers. J Virol (2011) 1.11
Unstimulated primary CD4+ T cells from HIV-1-positive elite suppressors are fully susceptible to HIV-1 entry and productive infection. J Virol (2010) 1.10
CD4+ T cells from elite suppressors are more susceptible to HIV-1 but produce fewer virions than cells from chronic progressors. Proc Natl Acad Sci U S A (2011) 1.05
Residual cell-associated unspliced HIV-1 RNA in peripheral blood of patients on potent antiretroviral therapy represents intracellular transcripts. Antivir Ther (2002) 1.05
Inhibitory potential of subpopulations of CD8+ T cells in HIV-1-infected elite suppressors. J Virol (2012) 1.00
Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 24.38
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol (2002) 10.37
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis (2003) 8.00
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 7.14
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood (2004) 7.09
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis (2008) 6.03
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Sampling-based approach to determining outcomes of patients lost to follow-up in antiretroviral therapy scale-up programs in Africa. JAMA (2008) 5.68
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation (2004) 4.87
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr (2010) 4.20
Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci Transl Med (2010) 4.07
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol (2009) 3.85
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83
Retention in care among HIV-infected patients in resource-limited settings: emerging insights and new directions. Curr HIV/AIDS Rep (2010) 3.80
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem (2009) 3.71
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS (2006) 3.70
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection. Nature (2010) 3.57
Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother (2004) 3.48
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis (2011) 3.38
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol (2007) 3.31
Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med (2012) 3.29
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Sampling-based approaches to improve estimation of mortality among patient dropouts: experience from a large PEPFAR-funded program in Western Kenya. PLoS One (2008) 3.19
Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA (2010) 3.14
Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One (2008) 3.13
A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis (2011) 3.10
Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS (2009) 3.08
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. J Acquir Immune Defic Syndr (2009) 2.99
Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS (2006) 2.98
HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr (2012) 2.95
CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med (2008) 2.94
Prevalence of Kaposi sarcoma-associated herpesvirus infection in homosexual men at beginning of and during the HIV epidemic. JAMA (2002) 2.91
Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol (2008) 2.90
Antiretroviral therapy and management of HIV infection. Lancet (2010) 2.84
Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis (2013) 2.82
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood (2013) 2.72